Notice2023-08327
Foreign-Trade Zone (FTZ) 7, Notification of Proposed Production Activity; AbbVie Ltd.; (Pharmaceutical Products); Barceloneta, Puerto Rico
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 20, 2023
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 76 (Thursday, April 20, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 76 (Thursday, April 20, 2023)]
[Notices]
[Page 24386]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-08327]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-29-2023]
Foreign-Trade Zone (FTZ) 7, Notification of Proposed Production
Activity; AbbVie Ltd.; (Pharmaceutical Products); Barceloneta, Puerto
Rico
AbbVie Ltd., submitted a notification of proposed production
activity to the FTZ Board (the Board) for its facility in Barceloneta,
Puerto Rico within Subzone 7I. The notification conforming to the
requirements of the Board's regulations (15 CFR 400.22) was received on
April 10, 2023.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>. The proposed finished
product(s) and material(s)/component(s) would be added to the
production authority that the Board previously approved for the
operation, as reflected on the Board's website.
The proposed finished product is RINVOQ[supreg] (upadacitinib)
tablets (duty-free).
The proposed foreign-status material is upadacitinib active
pharmaceutical ingredient (duty rate 6.5%).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#bed8cac4fecaccdfdadb90d9d1c8"><span class="__cf_email__" data-cfemail="6701131d27131506030249000811">[email protected]</span></a>. The closing period for their receipt is May 30, 2023.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Christopher Wedderburn at
<a href="/cdn-cgi/l/email-protection#55163d273c267b0230313130273720273b1521273431307b323a23"><span class="__cf_email__" data-cfemail="a7e4cfd5ced489f0c2c3c3c2d5c5d2d5c9e7d3d5c6c3c289c0c8d1">[email protected]</span></a>.
Dated: April 14, 2023.
Elizabeth Whiteman,
Acting Executive Secretary.
[FR Doc. 2023-08327 Filed 4-19-23; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 20, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.